Related Experiment Video
Updated: Apr 19, 2026
12:28
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
18.6K
Frontotemporal dementia: diagnosis, deficits and management
Nicholas T Bott1, Anneliese Radke, Melanie L Stephens
1Department of Neurology, Memory & Aging Center, University of California, 675 Nelson Rising Lane, Suite 190, San Francisco, CA 94158, USA.
Neurodegenerative Disease Management
|December 23, 2014
Summary
Frontotemporal dementia (FTD) presents diverse symptoms, posing diagnostic challenges. Early, comprehensive assessments are crucial for effective patient care and caregiver guidance.
Area of Science:
- Neurology
- Neuroscience
- Psychiatry
Background:
- Frontotemporal dementia (FTD) is a progressive neurodegenerative disorder characterized by diverse clinical presentations and underlying pathologies.
- Commonly observed symptoms include psychiatric prodrome, neuropsychiatric disturbances, and language impairments, complicating accurate diagnosis.
Purpose of the Study:
- To review the distinct syndromes within FTD.
- To highlight current research on cognitive, behavioral, and socio-emotional deficits in FTD.
- To address diagnostic challenges and summarize best practices for FTD management.
Main Methods:
- Review of existing literature on FTD syndromes and associated deficits.
- Discussion of diagnostic challenges and the need for sensitive assessment tools.
- Emphasis on comprehensive clinical evaluation including language, cognition, socio-emotional functioning, and neuroimaging.
Main Results:
- FTD syndromes exhibit varied presentations, necessitating tailored diagnostic approaches.
- Current research focuses on understanding the specific cognitive, behavioral, and socio-emotional impairments in FTD.
- Integrated assessment strategies are vital for early and accurate diagnosis.
Conclusions:
- Accurate and early diagnosis of FTD is critical for effective patient care and prognosis.
- Comprehensive assessments combining clinical evaluation, neuropsychological testing, and neuroimaging are essential.
- Improved understanding of FTD deficits will guide better management strategies and caregiver support.
Related Concept Videos
01:22Dementia l: Introduction
3
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
3
01:30Dementia
735
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
735
01:26Alzheimer's Disease: Overview
2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:29Alzheimer Disease l: Introduction
4
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
4
01:23Alzheimer Disease ll: Pathophysiology
2
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
2